Cardiovascular and Metabolic Disorders
Overview of the venous thromboembolism (VTE) therapeutics market
According to the market research analysts at Technavio, the global venous thromboembolism (VTE) therapeutics market is anticipated to witness impressive growth and post a CAGR of close to 7% over the forecast period. With the increase in surgical procedures such as hip and knee replacements, the market for VTE therapeutics is anticipated to have a positive outlook over the coming years. Joint replacement surgeries often result in long periods of immobility, increasing chances of developing deep vein thrombosis due to reduced blood flow. Moreover, according to the Center for Disease Control and Prevention, several cases or percutaneous coronary interventions, stent grafts, and coronary artery bypass grafting are performed each year, leading to increasing chances of developing thromboembolic events. This is also expected to boost the adoption of VTE therapeutics over the coming four years.
Patient assistance programs for VTE therapeutics, particularly for anticoagulants is an important trend gaining significant traction in the market. The vendors in the market are providing co-pay assistance to patients who are purchasing the indicated medications for VTE, for instance, Daiichi Sankyo’s drug Savaysa has an assistance program to provide financial assistance to those consuming the drug. Similarly, BMS provides support to patients buying its drugs through the Bristol-Myers Squibb Patient Assistance Foundation. With such assistance programs offered by pharmaceutical companies, the majority of patients feel inclined toward purchasing branded therapies, which will, in turn, propel this market’s growth prospects during the predicted period.
Competitive landscape and
Overview of the lifestyle drugs market
According to the market research analysts at Technavio, the global lifestyle drugs market will witness steady growth and will post a moderate CAGR of close to 3% over the forecast period. With the development of novel therapeutics, the market for lifestyle drugs is anticipated to have positive outlook over the coming years. As the market for depression are associated with high unmet medical needs, the need for novel therapeutics is on the rise, for instance, only 50% of individuals with depression receive any form of therapy. Out of these, only 25% of individuals receive a proper antidepressant dose and duration of treatment. Moreover, there are high unmet medical needs for erectile dysfunction. This has led the vendors to focus on developing novel therapeutics to increase the adoption rates for lifestyle drugs in the market.
The lifestyle drugs market is witnessing a sharp increase in mergers and acquisitions among the vendors which is one of the important trends gaining significant traction in the market. The vendors are pursuing inorganic growth strategies such as acquisitions and partnerships to expand their lifestyle drugs portfolio and to significantly improve their overall market presence. For example, in August 2015, Allergan completed the acquisition of Naurex. The acquisition enhanced Allergan’s portfolio of depression drugs with the addition of rapastinel. Such initiatives will contribute to the growth of the lifestyle drugs market over the next four years.
Competitive landscape and key vendors
The global lifestyle drugs market is highly fragmented with the presence of several key vendors such as Allergen
Global outlook of the diabetic therapeutic market
Technavio’s market research analysts predict the global diabetic therapeutic market to grow steadily during the forecast period and post a CAGR of more than 7% by 2021. This industry research report identifies the increasing focus on the self-management of diabetes to be one of the major factors that will have a positive impact on the growth of this market in the coming years. With the recent years witnessing an increase in number of people diagnosed with type 1 diabetes, there has been considerable increase in the adoption of insulin delivery systems. Focusing on skipping the need to schedule appointments and reduce expenses for clinical visits, increases the adoption of insulin delivery systems, where individuals use insulin injections at home under the guidance of a physician. This led to the introduction of insulin pens, pumps, and jet injectors, which, in turn, will drive the growth of the diabetic therapeutics market.
In terms of geographical regions, the Americas will be the major revenue contributor to the diabetic therapeutics market throughout the predicted period. The increasing prevalence of diabetes in countries such as the US, which provides opportunities for vendors to develop new, more efficient, and safer drugs will be the major factor driving market growth in this segment.
Competitive landscape and key vendors
Characterized by the presence of numerous small and large-scale vendors, this market appears to be highly competitive. The market is dominated by the major players such as AstraZeneca, Novo
Overview of the global pharmerging markets
Technavio’s market research analyst predicts the global pharmerging markets to grow steadily at a CAGR of around 13% by 2021. One of the primary drivers for this market is the increasing focus toward biosimilar in potential areas. As most of the patents for originator biologics have expired, the vendors are focusing on the development of duplicate copies of biologics, called biosimilars. These biosimilars provide the same efficacy as that of parent molecule but at a cheaper cost. The availability of cheap manufacturing resources such as land and labor has made the pharmerging market an important option for the development of these biosimilars. For instance, in 2014 trastuzumab, (a biosimilar of CANMab), which is indicated for the treatment of metastatic breast cancer was launched in India. Moreover, the on-going strong market growth in therapeutic areas will contribute further to higher penetration of the pharmerging markets over the next few years.
One of the latest trends gaining traction in this market is the rise in the positive outlook through the adoption of targeted therapies. With the growing incidences of chronic diseases such as cancer, which requires specific therapies for effective treatment, the implementation of targeted therapies is expected to witness substantial upward momentum. Research studies have demonstrated that targeted therapy has increased the survival rate and the cure rate in cancer patients. These drugs are expected to work effectively in the treatment of various cancers such as
Overview of the global compression therapy market
Technavio’s market research analyst predicts that the global compression therapy market will grow at a CAGR of more than 5% during the forecast period. The emergence of sequential compression therapy systems is anticipated to have a positive influence on the market, due to its growing use in several applications. Sequential calf compression and graduated compression stockings are increasingly being used for prophylaxis in neurosurgery for the prevention of PE and DVT. Also, the intraoperative sequential compression device systems are recommended during prolonged laparoscopic surgery to counter altered venous blood return from the lower extremities and subsequent cardiac depression caused by pneumoperitoneum. Sequential compression is an effective therapy, which generates results within 1-2 hours per day when compared to other alternatives that take 12-48 hours to achieve the same outcome. With an increase in the number of surgical procedures, the chances of developing thromboembolic events, which require treatment using compression therapy systems will also grow, further contributing to the growth of the overall market.
Geographically, the APAC region will witness the fastest growth rate in the global market during the forecast period. Much of the region’s growth can be attributed to the rising incidences of chronic conditions such as diabetes and VTE coupled with recent product innovations. The growing awareness among physicians about new compression systems will bring substantial growth opportunities in the market. Moreover, with the increasing demand for compression therapy in sports applications will further fuel the market growth in the APAC
Overview of the global infantile spasms therapeutics market
The global infantile spasms therapeutics market is anticipated to grow at a steady rate and will post a CAGR of above 2% during the forecast period. One of the primary drivers for this market is the growing scientific advancements in the infantile spasms therapeutic industry. Scientific advancements are helping physicians in early diagnosis, which is a crucial parameter in increasing life expectancy. Accurate diagnosis of infantile spasms can have a significant influence on the physician's decision-making process to prescribe a treatment regimen for individuals. For instance, technological advancements in medical imaging have improved the diagnosis of infantile spasms. Such scientific advantages will help in reducing the undiagnosed population, thereby raising the penetration rate of infantile spasm drugs.
In terms of geography, the Americas accounted for the maximum market share during 2016 and will continue to dominate the market for the next few years. The US is the single largest regional market in the infantile spasms drugs market in the Americas. The market is expected to experience steady growth owing to the increasing number of infantile spasms patients in this region. Also, the number of patients diagnosed with infantile spasm is estimated to be nearly half of the total number of patients in the region. To reduce the number of undiagnosed cases the region is witnessing various awareness programs and initiatives. For instance, in the US, the Epilepsy Foundation of Hawaii encouraged its members to dress in purple or a day, to create awareness regarding epilepsy and its related diseases.
Competitive landscape and key vendors
At present, the global infantile spasm therapeutics market is served by a limited number of vendors, this makes the market lucrative and provides immense growth opportunities. The
There is currently intense competition in the cardiovascular and metabolic disorder treatment market. Despite a wide range of drugs available for cardiovascular and metabolic disorders, these conditions remain the leading cause of death in both developed and developing countries, due in part to the rising number of people with sedentary lifestyles globally.
Big players in the pharmaceutical industry are entering the market and focusing on developing innovative compounds for novel targets in order to preserve or restore the physiological functions of patients. Furthermore, pharmaceutical companies are investing significantly in targeted marketing activities.